IGC Pharma (IGC) Equity Ratio (2016 - 2025)
IGC Pharma (IGC) has disclosed Equity Ratio for 15 consecutive years, with 0.83 as the latest value for Q3 2025.
- On a quarterly basis, Equity Ratio rose 16.74% to 0.83 in Q3 2025 year-over-year; TTM through Sep 2025 was 0.83, a 16.74% increase, with the full-year FY2025 number at 0.72, down 2.12% from a year prior.
- Equity Ratio was 0.83 for Q3 2025 at IGC Pharma, up from 0.77 in the prior quarter.
- In the past five years, Equity Ratio ranged from a high of 0.94 in Q4 2021 to a low of 0.69 in Q4 2024.
- A 5-year average of 0.84 and a median of 0.85 in 2023 define the central range for Equity Ratio.
- Peak YoY movement for Equity Ratio: decreased 16.7% in 2024, then increased 16.74% in 2025.
- IGC Pharma's Equity Ratio stood at 0.94 in 2021, then decreased by 3.12% to 0.91 in 2022, then decreased by 11.9% to 0.8 in 2023, then dropped by 14.25% to 0.69 in 2024, then increased by 20.46% to 0.83 in 2025.
- Per Business Quant, the three most recent readings for IGC's Equity Ratio are 0.83 (Q3 2025), 0.77 (Q2 2025), and 0.72 (Q1 2025).